152 related articles for article (PubMed ID: 9603175)
1. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines.
Beatty PR; Krams SM; Esquivel CO; Martinez OM
Transplantation; 1998 May; 65(9):1248-55. PubMed ID: 9603175
[TBL] [Abstract][Full Text] [Related]
2. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells.
Chen C; Johnston TD; Jeon H; Gedaly R; McHugh P; Ranjan D
J Surg Res; 2009 May; 153(1):156-61. PubMed ID: 18486150
[TBL] [Abstract][Full Text] [Related]
4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine promotes epstein-barr virus-infected human B-cell transformation assayed by three correlated assay methods.
Chen C; Johnston TD; Jeon H; Gedaly R; McHugh P; Ranjan D
Transplant Proc; 2009; 41(1):366-70. PubMed ID: 19249558
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
Tanner JE; Menezes J
Blood; 1994 Dec; 84(11):3956-64. PubMed ID: 7949151
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
[TBL] [Abstract][Full Text] [Related]
8. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
Estrov Z; Kurzrock R; Pocsik E; Pathak S; Kantarjian HM; Zipf TF; Harris D; Talpaz M; Aggarwal BB
J Exp Med; 1993 Mar; 177(3):763-74. PubMed ID: 8382256
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
Wilson AD; Redchenko I; Williams NA; Morgan AJ
Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E inhibits cyclosporin A and H2O2 promoted Epstein-Barr virus (EBV) transformation of human B cells as assayed by EBV oncogene LMP1 expression.
Chen C; Reddy KS; Johnston TD; Khan TT; Ranjan D
J Surg Res; 2003 Aug; 113(2):228-33. PubMed ID: 12957134
[TBL] [Abstract][Full Text] [Related]
11. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection process.
Krook H; Wennberg L; Hagberg A; Song Z; Groth CG; Korsgren O
Transplantation; 2002 Oct; 74(8):1084-9. PubMed ID: 12438951
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of Epstein-Barr virus-infected human B cell growth by physiological concentrations of 4-hydroxynonenal.
Ranjan D; Chen C; Johnston TD; Jeon H; Ibrahim M; Drake J; Butterfield DA
Cell Biochem Funct; 2006; 24(2):147-52. PubMed ID: 15651079
[TBL] [Abstract][Full Text] [Related]
15. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.
Carmona A; Díaz-Ricart M; Palomo M; Molina P; Pino M; Rovira M; Escolar G; Carreras E
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1439-45. PubMed ID: 23845694
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclosporine on human B-cell lymphoma development in vivo.
Boyle TJ; Coles RE; Kizilbash AM; Lyerly HK
Surg Oncol; 1992 Feb; 1(1):79-86. PubMed ID: 1341239
[TBL] [Abstract][Full Text] [Related]
17. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.
Brewin J; Mancao C; Straathof K; Karlsson H; Samarasinghe S; Amrolia PJ; Pule M
Blood; 2009 Nov; 114(23):4792-803. PubMed ID: 19770360
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A and Tacrolimus Induce Functional Impairment and Inflammatory Reactions in Endothelial Progenitor Cells.
Meyer N; Brodowski L; von Kaisenberg C; Schröder-Heurich B; von Versen-Höynck F
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575860
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A-induced lipid and protein oxidation in human B-cells and in Epstein-Barr virus-infected B-cells is prevented by antioxidants.
Chen C; Jeon H; Johnston TD; Gedaly R; McHugh PP; Ranjan D
J Invest Surg; 2008; 21(4):201-8. PubMed ID: 18615317
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
Amundsen R; Åsberg A; Ohm IK; Christensen H
Drug Metab Dispos; 2012 Apr; 40(4):655-61. PubMed ID: 22205779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
